Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Q4 2024 Earnings Conference Call

March 26, 2025 - 4:30 PM ET

Learn More Webcast

Latest News

Mar 19, 2025 • 4:01pm EDT

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

Read Press Release

Mar 12, 2025 • 8:30am EDT

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

Mar 5, 2025 • 4:01pm EST

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

Mar 4, 2025 • 4:01pm EST

Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

View All SEC Filings

Q3 2024

Quarter Ended Sep 30, 2024

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Contacts

Corporate

Journey Medical Corporation
9237 East Via De Ventura
Suite 105
Scottsdale, AZ 85258
T: 480-434-6670
contact@jmcderm.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@jmcderm.com

Transfer Agent

VStock Transfer
Allison Niccolls
allison@vstocktransfer.com